The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
Healthcare M&A image Healthcare M&A » By The Online Investor Staff, updated Sun., Aug. 14, 1:49 PM Recent mergers and acquisitions in the Healthcare M&A category.

Slide #82. Alnylam Pharmaceuticals, Inc. Merck's Sirna Therapeutics Subsidiary

Acquirer: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Acquiree: Merck's Sirna Therapeutics Subsidiary
Details: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a leading RNAi therapeutics company, announced today that the previously announced acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. ("Sirna Therapeutics" or "Sirna") has closed, following the expiration of the Hart-Scott-Rodino waiting period. On January 10, 2014, Alnylam entered into a stock purchase agreement with Merck pursuant to which Alnylam agreed to purchase from Merck all of Merck's rights, title, and interest in and to all of the outstanding shares of common stock of Sirna Therapeutics. In consideration for the Sirna common stock, Alnylam paid Merck $25.0 million in cash. In addition, Alnylam agreed to issue to Merck 2,520,044 shares of Alnylam common stock, having a value of $150.0 million as calculated under the terms of the stock purchase agreement on the date of execution, and representing an approximately 3% ownership position in Alnylam's outstanding common stock. Alnylam issued 85% of the shares at the closing and will issue the remainder of shares upon the completion of certain technology transfer activities pursuant to the terms of the stock purchase agreement.

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference. Co. has four RNAi-based medicines, ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO™ (lumasiran) and Leqvio® (inclisiran). ONPATTRO is approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. GIVLAARI is approved for the treatment of adults with acute hepatic porphyria. Co. has approval for OXLUMO for the treatment of hyperoxaluria type 1 (PH1) in all age groups. Leqvio (inclisiran) is being developed for the treatment of adults with hypercholesterolemia or mixed dyslipidemia.

ALNY SEC Filing Email Alerts Service

Open the ALNY Page at The Online Investor »

Company Name:  Alnylam Pharmaceuticals Inc
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ALNY:  57
Total Market Value Held by ETFs:  $3.09B
Total Market Capitalization:  $27.85B
% of Market Cap. Held by ETFs:  11.08%

Open the ALNY Page at The Online Investor (in a new window) »

August 14, 2022    1:49 PM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree ALNY Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.26 out of 4)
35th percentile
(ranked lower than approx. 65% of all stocks covered)

Analysts' Target Price:
ALNY Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Healthcare M&A - Slide 82 of 100 | | Copyright © 1998 - 2022, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.